COVID-19 R&D – Vaccine Manufacturing Scaling

Milestones :: Perspectives :: Research


COVID-19 R&D – Vaccine Manufacturing Scaling

Johnson & Johnson Announces Collaboration to Expand Manufacturing Capabilities For its COVID-19 Vaccine Candidate in Support of the Company’s Goal to Supply More Than One Billion Vaccine Doses Globally
:: Company Signs Agreement with Emergent BioSolutions in the U.S. As Part of its Investment
:: First in Series of Anticipated Strategic Collaborations Designed to Further the Company’s Goal of Ensuring Global Supply of a Safe and Effective Vaccine for COVID-19
Apr 23, 2020

Moderna and Lonza Announce Worldwide Strategic Collaboration to Manufacture Moderna’s Vaccine (mRNA-1273) Against Novel Coronavirus
:: Collaboration goal to enable manufacturing of up to 1 billion doses per year
:: Technology transfer expected to begin in June 2020
:: First batches of mRNA-1273 expected to be manufactured at Lonza U.S. in July 2020
:: Collaboration leverages Lonza’s worldwide expertise in technology transfer and manufacturing
May 01, 2020